| Registro completo |
| Provedor de dados: |
BJID
|
| País: |
Brazil
|
| Título: |
Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil
|
| Autores: |
Focaccia,R.
Baraldo,D.C.M.
Ferraz,M.L.G.
Martinelli,A.L.C.
Carrilho,F.J.
Gonçales Jr.,F.L.
Pedroso,M.L.A.
Coelho,H.S.M.
Lacerda,M.A.
Brandão,C.E.
Mattos,A.A.
Lira,L.G.C.
Zamin Jr.,I.
Pinheiro,J.O.P.
Tovo,C.V.
Both,C.T.
Soares,J.A.S.
Dittrich,S.
|
| Data: |
2004-10-01
|
| Ano: |
2004
|
| Palavras-chave: |
HCV
Chronic hepatitis C
Genotype
Body weight
Brazil
|
| Resumo: |
Hepatitis C virus (HCV) infection is a serious public health problem, since 80% to 85% of HCV carriers develop a persistent infection that can progress into liver cirrhosis and hepatocarcinoma. Considering that the response of hepatitis C patients to combination therapy with interferon and ribavirin depends on HCV characteristics as well as on host features, we made a retrospective analysis of demographic and anthropometrical data and HCV genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil. The medical records of 4,996 patients were reviewed, 81% from public and 19% from private institutions. Patients' median age was 46 years, and there was a higher prevalence of male (62%) and white patients (80%). The analysis of HCV-infecting strains showed a predominance of genotype 1 (64%) over genotypes 2 and 3. The patients' mean weight was 70.6 kg, and 65% of the patients weighed less than 77kg. Overweight and obesity were observed in 37.8% and 13.6% of the patients, respectively. Since a body weight of 75 kg or less has been considered an independent factor that significantly increases the odds of achieving a sustained virological response, the Brazilian population seems to have a more favorable body weight profile to achieve a sustained response than the American and European populations. The finding that 65% of chronic hepatitis C patients have a body weight of 77 kg or less may have a positive pharmacoeconomic impact on the treatment of genotype 1 HCV patients with weight-based doses of peginterferon.
|
| Tipo: |
Info:eu-repo/semantics/article
|
| Idioma: |
Inglês
|
| Identificador: |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702004000500003
|
| Editor: |
Brazilian Society of Infectious Diseases
|
| Relação: |
10.1590/S1413-86702004000500003
|
| Formato: |
text/html
|
| Fonte: |
Brazilian Journal of Infectious Diseases v.8 n.5 2004
|
| Direitos: |
info:eu-repo/semantics/openAccess
|
|
